#United States #Carlsbad #NGS Technology #DNAe #LiDia-SEQ

DNAe Announces Early Access Program for LiDia-SEQ™

DNAe, a pioneer in Next-Generation Sequencing (NGS) technology, has recently rolled out an Early Access Program (EAP) designed to invite hospitals and research institutions to participate in the preliminary phases of their innovative diagnostic platform, LiDia-SEQ™. This initiative aims to showcase the remarkable capabilities of DNAe's first-in-class tests, which include the ground-breaking Bloodstream Infection/Antimicrobial Resistance (BSI/AMR) test.

The EAP offers clinical partners an exclusive preview of the results produced by these revolutionary tests, which are set to potentially change the landscape of diagnostic processes. As hospitals and clinics express their interest, they will gain access to the results generated by the BSI/AMR assay, which targets life-threatening bloodstream infections and antimicrobial resistance markers. This technology is poised to deliver results within hours, significantly reducing waiting times compared to traditional testing methods.

Starting in April 2026, Phase One of the Early Access Program will allow participating sites to send whole blood samples and culture isolates to DNAe for testing, marking a crucial step in refining the diagnostic experience and ensuring that the results are actionable and beneficial for healthcare systems. The second phase will advance to on-site placements of prototype LiDia-SEQ™ systems, allowing hospitals to run the BSI/AMR test directly within their facilities before it is commercially available.

CEO Samuel Reed has expressed his enthusiasm regarding the EAP's potential, remarking, "This is a pivotal moment in the evolution of the LiDia-SEQ™ platform. By collaborating with pioneering hospitals, we will not only highlight the transformative results our tests can deliver but also gather valuable data on their effectiveness compared to traditional methods."

The BSI/AMR test itself is designed to detect bacterial and fungal pathogens in whole blood, providing crucial insights into antimicrobial resistance, all while maintaining clinical relevance with low detection limits. It will initially target around 7,200 bacteria and 750 fungi, showcasing a comprehensive approach to infectious disease diagnostics.

DNAe's rapid-response, NGS-based system will facilitate near-patient diagnostics, aligning with the urgent need for swift and accurate testing in critical care settings. As hospitals sign on for the EAP, they will be empowered to explore the platform's potential to enhance patient care, expedite treatment pathways, and optimize clinical outcomes.

Furthermore, DNAe’s focus extends beyond merely infectious diseases. The company is also developing tests for monitoring circulating tumor DNA, underscoring its commitment to broadening the horizon of genomic analysis across various medical conditions.

The Early Access Program not only represents a forward-thinking approach to healthcare but also positions DNAe as a leader in the evolution of diagnostic technologies. As the landscape of healthcare continues to evolve, programs like the EAP will undoubtedly play a critical role in advancing clinical practices and enhancing patient outcomes.

With expressions of interest currently being accepted on DNAe's website, hospitals and research institutions are advised to engage with this unique opportunity to be at the forefront of next-generation diagnostics. The future of healthcare is undoubtedly innovative, and with developments such as the LiDia-SEQ™ platform, DNAe is set to lead the change.

For more information about the Early Access Program and to express interest, please visit DNAe’s official website.